Breast Cancer Research and Treatment

, Volume 138, Issue 1, pp 241–248 | Cite as

Time-trends in survival in young women with breast cancer in a SEER population-based study

  • Foluso O. Ademuyiwa
  • Adrienne Groman
  • Chi-Chen Hong
  • Austin Miller
  • Shicha Kumar
  • Ellis Levine
  • Deborah Erwin
  • Christine Ambrosone


Mortality improvements in young women with breast cancer (BC) may be attributable to treatment advances; screening likely plays a less significant role as mammography is not recommended <40. We examined time-trends in outcome in a cohort of young women. Our goal was to determine the contributions of treatment and screening to mortality improvements and evaluate whether differential outcomes by ER status exist. Using SEER, patients (73,447) were divided into three categories by diagnosis year (1990–1994, 1995–1999, 2000–2004) and also categorized as <40 or 40–50 years. Multivariate analysis was done to investigate the association of survival with time period for both age groups by ER status. Hazard ratios (HR) for mortality in women 40–50 with ER positive BC declined over time. With 1990–1994 as referent, the HR in 1995–1999 was 0.77 (0.69–0.86) and 0.65 (0.59–0.71) in 2000–2004 (p < 0.001). Women <40 with ER positive BC also had improvements over time. In ER negative patients, the degree of improvements over time was less than that seen in ER positive women. We report a survival disparity over time in young women by ER status. Patients with ER negative disease have not had the degree of improvements over time as seen in ER positive disease. Therefore, mortality improvements in young women with ER positive BC may be attributed to treatment advances with endocrine agents.


Breast cancer Young age Survival Trends 

Supplementary material

10549_2013_2425_MOESM1_ESM.doc (48 kb)
Supplementary material 1 (DOC 48 kb)


  1. 1.
    ACS (2011) Breast Cancer Facts & Figures 2011–2012. American Cancer Society, AtlantaGoogle Scholar
  2. 2.
    Bleyer A, Barr R, Hayes-Lattin B et al (2008) The distinctive biology of cancer in adolescents and young adults. Nat Rev Cancer 8:288–298PubMedCrossRefGoogle Scholar
  3. 3.
    de la Rochefordiere A, Asselain B, Campana F et al (1993) Age as prognostic factor in premenopausal breast carcinoma. Lancet 341:1039–1043PubMedCrossRefGoogle Scholar
  4. 4.
    Anders CK, Hsu DS, Broadwater G et al (2008) Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol 26:3324–3330PubMedCrossRefGoogle Scholar
  5. 5.
    Kurian AW, Fish K, Shema SJ et al (2010) Lifetime risks of specific breast cancer subtypes among women in four racial/ethnic groups. Breast Cancer Res 12:R99PubMedCrossRefGoogle Scholar
  6. 6.
    Telli ML, Chang ET, Kurian AW et al (2011) Asian ethnicity and breast cancer subtypes: a study from the California Cancer Registry. Breast Cancer Res Treat 127:471–478PubMedCrossRefGoogle Scholar
  7. 7.
    Carey LA, Perou CM, Livasy CA et al (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295:2492–2502PubMedCrossRefGoogle Scholar
  8. 8.
    Colleoni M, Rotmensz N, Robertson C et al (2002) Very young women (<35 years) with operable breast cancer: features of disease at presentation. Ann Oncol 13:273–279PubMedCrossRefGoogle Scholar
  9. 9.
    Lund MJ, Trivers KF, Porter PL et al (2009) Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA. Breast Cancer Res Treat 113:357–370PubMedCrossRefGoogle Scholar
  10. 10.
    Althuis MD, Brogan DD, Coates RJ et al (2003) Breast cancers among very young premenopausal women (United States). Cancer Causes Control 14:151–160PubMedCrossRefGoogle Scholar
  11. 11.
    Shavers VL, Harlan LC, Stevens JL (2003) Racial/ethnic variation in clinical presentation, treatment, and survival among breast cancer patients under age 35. Cancer 97:134–147PubMedCrossRefGoogle Scholar
  12. 12.
    Chung M, Chang HR, Bland KI et al (1996) Younger women with breast carcinoma have a poorer prognosis than older women. Cancer 77:97–103PubMedCrossRefGoogle Scholar
  13. 13.
    Adami HO, Malker B, Holmberg L et al (1986) The relation between survival and age at diagnosis in breast cancer. N Engl J Med 315:559–563PubMedCrossRefGoogle Scholar
  14. 14.
    Winchester DP, Osteen RT, Menck HR (1996) The National Cancer Data Base report on breast carcinoma characteristics and outcome in relation to age. Cancer 78:1838–1843PubMedCrossRefGoogle Scholar
  15. 15.
    Berry DA, Cronin KA, Plevritis SK et al (2005) Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 353:1784–1792PubMedCrossRefGoogle Scholar
  16. 16.
    Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717Google Scholar
  17. 17.
    Giordano SH, Buzdar AU, Smith TL et al (2004) Is breast cancer survival improving? Cancer 100:44–52PubMedCrossRefGoogle Scholar
  18. 18.
    Dawood S, Broglio K, Gonzalez-Angulo AM et al (2008) Trends in survival over the past two decades among white and black patients with newly diagnosed stage IV breast cancer. J Clin Oncol 26:4891–4898PubMedCrossRefGoogle Scholar
  19. 19.
    Eheman C, Henley SJ, Ballard-Barbash R et al (2012) Annual report to the nation on the status of cancer, 1975–2008, featuring cancers associated with excess weight and lack of sufficient physical activity. Cancer 118(9):2338–2366Google Scholar
  20. 20.
    Howlader N, Noone AM, Krapcho M et al (2012) SEER Cancer Statistics Review, 1975–2009. National Cancer Institute, BethesdaGoogle Scholar
  21. 21.
    Haggstrom DA, Quale C, Smith-Bindman R (2005) Differences in the quality of breast cancer care among vulnerable populations. Cancer 104:2347–2358PubMedCrossRefGoogle Scholar
  22. 22.
    Kadaoui N, Guay M, Baron G et al (2012) Breast cancer screening practices for women aged 35 to 49 and 70 and older. Can Fam Physician 58:e47–e53PubMedGoogle Scholar
  23. 23.
    Elkin EB, Ishill NM, Snow JG et al (2010) Geographic access and the use of screening mammography. Med Care 48:349–356PubMedCrossRefGoogle Scholar
  24. 24.
    Autier P, Boniol M, Gavin A et al (2011) Breast cancer mortality in neighbouring European countries with different levels of screening but similar access to treatment: trend analysis of WHO mortality database. BMJ 343:d4411PubMedCrossRefGoogle Scholar
  25. 25.
    Porter PL, El-Bastawissi AY, Mandelson MT et al (1999) Breast tumor characteristics as predictors of mammographic detection: comparison of interval- and screen-detected cancers. J Natl Cancer Inst 91:2020–2028PubMedCrossRefGoogle Scholar
  26. 26.
    Collett K, Stefansson IM, Eide J et al (2005) A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors. Cancer Epidemiol Biomarkers Prev 14:1108–1112PubMedCrossRefGoogle Scholar
  27. 27.
    Pagani O, O’Neill A, Castiglione M et al (1998) Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI. Eur J Cancer 34:632–640PubMedCrossRefGoogle Scholar
  28. 28.
    Parulekar WR, Day AG, Ottaway JA et al (2005) Incidence and prognostic impact of amenorrhea during adjuvant therapy in high-risk premenopausal breast cancer: analysis of a National Cancer Institute of Canada Clinical Trials Group Study–NCIC CTG MA.5. J Clin Oncol 23:6002–6008PubMedCrossRefGoogle Scholar
  29. 29.
    Ademuyiwa FO, Groman A, O’Connor T et al (2011) Impact of body mass index on clinical outcomes in triple-negative breast cancer. Cancer 117:4132–4140PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Foluso O. Ademuyiwa
    • 1
  • Adrienne Groman
    • 2
  • Chi-Chen Hong
    • 3
  • Austin Miller
    • 2
  • Shicha Kumar
    • 4
  • Ellis Levine
    • 6
  • Deborah Erwin
    • 5
  • Christine Ambrosone
    • 3
  1. 1.Division of Oncology, Department of MedicineWashington University in St. Louis School of MedicineSt. LouisUSA
  2. 2.Department of BiostatisticsRoswell Park Cancer InstituteBuffaloUSA
  3. 3.Department of Cancer Prevention and ControlRoswell Park Cancer InstituteBuffaloUSA
  4. 4.Department of Surgical OncologyRoswell Park Cancer InstituteBuffaloUSA
  5. 5.Division of Cancer Prevention and Population Sciences, Office of Cancer Health Disparities ResearchRoswell Park Cancer InstituteBuffaloUSA
  6. 6.Department of MedicineRoswell Park Cancer InstituteBuffaloUSA

Personalised recommendations